

BIBLIOGRAFIA

- Abbott, A. Doctor seek lost data on Alzheimer's vaccine. *Nature*. 2004. **430**: 715.
- Alisi, M.A., Brufani, M., Filocamo, L., Gostoli, G., Licandro, E., Cesta, M.C., Lappa, S., Marchesini, D. and Pagella, P. Synthesis and structure-activity relationships of new Acetylcholinesterase inhibitors:morpholinoalkylcarbamoyloxyseroline derivatives. (1995) *Bioorg. Med. Chem. Lett.* 1995. **18**: 2077-2080.
- Astier, A. and Petitjean, D. Pharmacokinetics of an anticholinesterasic agent (eserin N-oxide) in humans after administration of two galenic forms. *J. Pharm. Clin.* 1985.**4**: 521-527.
- Axelsen, P.H., Harel, M., Silman, I. and Sussman, J.L. Structure and dynamics of the active site gorge of Acetylcholinesterase: Synergistic use of molecular dynamics simulation and X-ray crystallography. *Protein Science*.1994. **3**: 188-197.
- Barber, K.L., Mesulam, M.M., Kraft, G.A., and Klein, W.L. Butyrylcholinesterase alters the aggregation of A β amyloid. *Proc. Soc. Neurosci.*1996. **22**: 1172.
- Bar-On, P., Millard, C.B., Harel, M., Dvir., H., Enz. A. Sussman, J.L. and Silman, I. Kinetic and structural studies on the interaction of the Cholinesterases with the anti-Alzheimer drug Rivastigmine. *Biochemistry*. 2002. **41**: 3555-3564.
- Bartolucci, C., Perola, E., Cellai, L., Brufani, M. and Lamba, D. "Back door" opening implied by the crystal structure of a carbamoylated Acetylcholinesterase. *Biochemistry*. 1999. **38**: 5714-5719.
- Bartolucci, C., Perola, E., Pilger, C., Fels, G. and Lamba, D. Three-dimensional structure of a complex of galanthamine (Nivalin) with Acetylcholinesterase from *Torpedo Californica*: implications for the design of new anti-Alzheimer drugs. *Proteins*. 2001. **42**: 182-191.
- Bazelyansky, M., Robey, E. and Kirsch J. F. Fractional diffusion-limited component of reactions catalyzed by Acetylcholinesterase. *Biochemistry*. 1986. **25**:125-130.
- Becker, R. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In: Becker, R. and Giacobini, E. eds.*Cholinergic Basis for Alzheimer Therapy*. Birkhauser Boston, 1991: 1-22.

- Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E. The Protein Data Bank. *Nucleic Acids Research*. 2000. **28**: 235-242.
- Blow, D.M. and Crick F.H.C. The treatment of errors in the isomorphous replacement method. *Acta Cryst.* 1959. **12**: 794-804.
- Blundell, T.L., Johnson, M.S., Overington, J.P. and Sali, A. Knowledge-based protein modelling and the design of novel molecules. In: Hook, J.B. and Poste, G., eds. *Protein design and the development of new therapeutics and vaccines*. New York, Plenum Press, 1990: 209-249.
- Bores, G.M. and Kosley, R.W. Galanthamine derivatives for the treatment of Alzheimer's disease. *Drugs of the future*. 1996a. **21**: 621-635.
- Bores, G.M., Huger, F.P., Petko, W., Mutlib, A.E., Camacho, F., Rush, D. K., Selk, D.E., Wolf, V., Kosley, R.W., Davis, L. and Vargas, H.M. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. *J. Pharmacology and Experimental Therapeutics*. 1996b. **277**: 728-738.
- Bourne, Y., Taylor, P., Radic, Z. and Marchot, P. Structural insight into ligand interaction at the Peripheral anionic Site. *EMBO J.* 2003. **22**: 1-12.
- Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 1976. **72**: 248-254.
- Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunsleve, R.W., Jiang, J.S., Kusewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T. and Warren, G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr.D.* 1998. **54**: 905-921.
- Brünger, A.T. Free R-value-a novel statistical quantity for assessing the accuracy of crystal structures. *Nature* 1992. **355**: 472-475.
- Camps, P., Cusack, B., Mallender, W.D., Achab, R.E., Morral, J., Munoz-Torrero D. and Rosenberry, T.L. Huprine X is a novel high-affinity inhibitors of Acetylcholinesterase that is of interest for treatment of Alzheimer's disease. *Mol. Pharmacol.* 2000. **57**: 409-417.

- Capsoni, S., Giannotta, S., Stebel, M., Garcia, A.A., De Rosa, R., Villetti, G., Imbimbo, B.P., Pietra, C. and Cattaneo, A. Ganstigmine and Donepezil improve neurodegeneration in AD11 anti-nerve growth factor transgenic mice. *Am.J.Alzheimers Dis.* 2004, **19**: 153-160.
- Carlier, P.R., Chow, E.S., Han, Y., Liu, J., El Yazal, J. and Pang, Y.-P. Heterodimeric tacrine-based Acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. *J. Med. Chem.* 1999a. **35**: 590-601.
- Carlier, P.R., Du, D.M., Han, Y., Liu, J. and Pang, Y.-P. Potent, easily synthesized huperzine A-tacrine hybrid Acetylcholinesterase inhibitors. *Bioorg. Med. Chem. Lett.* 1999b. **9**: 2335-2338.
- Carlier, P.R., Du, D.M., Han, Y., Liu, J., Perola, E., Williams, I.D. and Pang, Y.-P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. *Angew. Chem. Int. Ed. Engl.* 2000. **39**: 1775-1777.
- Cassano, T., Carratù, M.R., Cosuccia, A., Di Giovanni, V., Steardo, L., Cuomo, V. and Trabace, L. Preclinical progress with CHF2819, a novel orally active Acetylcholinesterase inhibitor. *Drug Development Research.* 2002. **56**: 354-368.
- Catinella, S., Pelizzi, N., Puccini, P., Marchetti, S., Zanol, M., Acerbi, D. and Ventura, P. Phase I metabolism of ganstigmine. Rat, dog, monkey and human liver microsomal extracts investigated by liquid chromatography electrospray tandem mass spectrometry. *J. Mass Spectrom.* 2001. **36**: 1287-1293.
- Chatonnet, A. and Lockridge, O. Comparison of Butyrylcholinesterase and Acetylcholinesterase. *Biochem. J.* 1989. **260**: 625-634.
- Citron, M. Strategy for disease modification in Alzheimer's disease. *Nat. Neurosci.* 2004. **5**: 677-685.
- Collaborative Computational Project N° 4. The CCP4 Suite: Programs for protein Crystallography. *Acta Crystallogr. D.* 1994. **50**: 760-763.
- Dajas-Bailador, F.A., Heimala, K. and Wonnacott, S. The allosteric potentiation of nicotinic acetylcholine receptors by galanthamine is transduced into cellular responses in neurons: Ca²⁺ signals and neurotransmitter release. *Mol. Pharmacol.* 2003. **64**: 1217-1226.

- Davis, K.L. and Powchik, P. Tacrine. *Lancet* 1995. **345**: 625-630.
- Dolginova, E., Roth, E., Silman, I. and Weiner, L.M. Chemical modification of Torpedo Acetylcholinesterase by disulfides: appearance of a “molten globule” state. *Biochemistry*. 1992. **31**: 12248-12254.
- Doucet-Personeni, C., Bentley, P.D., Fletcher, R.J., Kinkaid, A., Kryger, G., Pirard, B., Taylor, A., Taylor, R., Taylor, J., Viner, R., Silman, I., Sussman, J.L., Greenblatt, H.M. and Lewis, T. A structure-based design approach to novel reversible AChE inhibitors. *J. Med. Chem.* 2001. **44**: 3203-3215.
- Dougherty, D.A. Cation- π interactions in chemistry and biology: a new view of benzene, Phe, Tyr and Trp. *Science*. 1996. **271**: 163-168.
- Drenth, J. Principles of protein X-ray crystallography. New York, Springer-Verlag, 1994.
- Ducroix, A. and Giegè, R. Crystallization of Nucleic Acids and Proteins. A Practical Approach. The Practical Approach Series. Oxford, UK, Oxford University Press, 1992.
- Dvir, H., Jiang, H.L., Wong, D.M., Harel, M., Chetrit, M., He, X.C., Jin, G.Y., Yu, G.L., Tang, X.C., Silman, I., Bai, D.L. and Sussman, J.L. X-ray structures of torpedo californica Acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. *Biochemistry*. 2002a. **41**: 10810-10818.
- Dvir, H., Wong, D.M., Harel, M., Barril, X., Orozco, M., Luque, F.J., Munoz-Torrero, D., Camps, P., Rosenberry, T.L., Silman, I. and Sussman, J.L. 3D Structure of Torpedo californica Acetylcholinesterase complexed with Huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. *Biochemistry*. 2002b **41**: 2970-2981.
- Eichler, J., Anselmet, A., Sussman, J.L., Massoulié, J. and Silman, I. Differential effects of “peripheral” site ligands on Torpedo and Chicken Acetylcholinesterase. *Mol. Pharmacol.* 1994. **45**: 335-340.
- Ellman, G.L., Courtney, K.D., Andres Jr., A.V. and Featherstone, R.M. A new and rapid colorimetric determination of Acetylcholinesterase activity. *Biochem. Pharmacol.* 1961. **7**: 88-95.

- Engh, R.A. and Huber, R. Accurate bond and angle parameters for X-ray protein structure refinement. *Acta Cryst.* 1991. **A47**: 392-400.
- Enz, A., Amstutz, R., Boddeke, H., Gmelin, G. and Malanowski, J. Brain selective inhibition of Acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. *Prog. Brain. Res.* 1993. **98**: 431-438.
- Enz, A. and Floersheim, P. Cholinesterase inhibitors: an overview of their mechanisms of action in Alzheimer's disease. In: Becker, R. and Giacobini, E., eds. *Alzheimer Disease: From Molecular Biology to Therapy*. Birkhauser Boston, 1996: 211-215.
- Faerman, C., Ripoll, D., Bon, S., Le Feuvre, Y., Morel, N., Massoulié, J., Sussman, J.L. and Silman, I. Site-directed mutants designed to test back-door hypothesis of Acetylcholinesterase function. *FEBS Lett.* 1996. **386**: 65-71.
- Felder, C.E., Harel, M., Silman, I. and Sussman, J.L. Structure of a complex of the potent and specific inhibitor Bw284c51 with Torpedo californica Acetylcholinesterase. *Acta Crystallogr.D.* 2002. **58**: 1765-1761.
- Friedhoff, P., Von Bergen, M., Mandelkow, E-M., Davies, P., Mandelkow, E. A nucleated assembly mechanism of Alzheimer paired helical filaments. *Proc.Natl.Acad.Sci.U.S.A.* 1998. **95**: 15712-15717.
- Galasko, D.R. Early Detection and differentiation of Alzheimer's Disease. www.medscape.com.
- Galli, A., Renzi, G., Grazzini, E., Bartolini, R., Aiello-Malmberg, P. and Bartolini, A. Reversible inhibition of Acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine. *Biochem.Pharmacol.* 1982. **31**: 1233-1238.
- Garman, E.F. and Schneider, T.R. Macromolecular cryocrystallography. *J. Appl. Cryst.* 1997. **30**: 211-237.
- Giacobini, E., Somani, S., McIlhni, M., Downen, M. and Hallak, M. Pharmacokinetics and pharmacodynamics of Physostigmine after intravenous administration in beagle dogs. *Neuropharmacol.* 1987. **26**: 831-836.
- Giacovazzo, C. Direct phasing in crystallography. Fundamental and applications. Oxford University Press, 1999.

- Giles, K. Interactions underlying subunit association in Cholinesterases. *Prot. Eng.* 1997. **10** : 677-685.
- Giles, K., Raves, M.L., Silman, I. and Sussman, J.L. How three-fingered snake toxins recognise their targets: Acetylcholinesterase-fasciculin complex, a case-study. In: *Theoretical and computational methods in genome research*. Suhai. New York, Plenum Press, 1997: 303-315.
- Gilson, M.K., Straatsma, T.P., McCammon, J.A., Ripoll, D.R., Faerman, C.H., Axelsen, P., Silman, I. And Sussman, J.L. Open “back door” in a molecular dynamics simulation of Acetylcholinesterase. *Science*. 1994. **263**: 1276-1278.
- Glusker, J.P., Lewis, M., and Rossi, M. Crystal Structure Analysis for Chemists and Biologists. VCH, 1994.
- Golicnik, M. and Stojan, J. Transient kinetic approach to the study of Acetylcholinesterase reversible inhibition by Eseroline. *J.Enzyme Inhib. Med.Chem.* 2002. **17**: 279-285.
- Green, D.W., Ingram, V.M. and Perutz, M.F. The structure of haemoglobin IV. Sign determination by the isomorphous replacement method. *Proc. Roy.Soc. A* 1954. **225**: 287.
- Greenblatt, H.M., Kryger, G., Lewis, T., Silman, I. and Sussman, J.L. Structure of Acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. *FEBS Lett.* 1999. **463**: 321-326.
- Greenblatt, H.M., Guillou, C., Guénard, D., Argaman, A., Botti, S., Badet, B., Thal, C., Silman, I. and Sussman, J.L. The Complex of a bivalent derivative of galanthamine with Torpedo Acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. *J.Am.Chem.Soc.* Web release date: 4 Nov.2004.
- Greenfield, S. Acetylcholinesterase may have novel functions in the brain. *Trends Neurosci.* 1984. **7**: 364-368.
- Greig, N.H., Pei, X.F., Soncrant, T.T., Ingram, D.K. and Brossi, A. Phenserine and ring C hetero-analogues: drug candidates for treatment of Alzheimer’s disease. *Med. Res. Rev.* 1995. **15**: 3-31.
- Greig, N.H., Ingram, D., Wallace, W.C., Utsuki, T., Yu, Q.S., Holloway, H.W., Pei, X.F., Haroutunian, V., Lahiri, D., Brossi, A. and Soncrant,

- T.T. Phenserine: a selective, long-acting abd brain-directed Acetylcholinesterase inhibitor affecting cognition and β -APP processing. In: Becker, B., Giacobini, E., Robert, P., eds. *Alzheimer's disease: molecular biology to therapy*. Birkhäuser, Boston, 1996: 231-237.
- Grochulski, P., Li, Y., Schrag, J.D. and Cygler, M. Two conformational states of *Candida rugosa* lipase. *Protein Science*. 1994. **3**: 82-91.
- Guillozet, A.L., Smiley, J.F., Mash, D.C. and Mesulam, M.M. Butyrylcholinesterase in the life cycle of amyloid plaques. *Ann. Neurol.* 1997. **42**: 909-918.
- Han, S.Y., Sweeney, J.E., Bachman, E.S., Schweige, E.J., Forloni G., Coyle, J.T., Davis, B.M. and Jouilliè, M.M. Chemical and pharmacological characterization of galanthamine, an Acetylcholinesterase inhibitor, and its derivatives- a potential application in Alzheimer's disease. *Eur. J. Med. Chem.* 1992. **27**: 673-687.
- Han, Y.F., Li, C.P., Chow, E., Wang, H., Pang, Y.-P. and Carlier P.R. Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline- based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. *Bioorg. Med. Chem. Lett.* 1999. **7**: 2569-2575.
- Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P.H., Silman, I. And Sussman, J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of Acetylcholinesterase. *Proc. Natl. Acad. Sci. USA*. 1993. **90**: 9031-9035.
- Harel, M., Kleywegt, G.J., Ravelli, R.B.G., Silman, I. And Sussman, J.L. Crystal structure of an Acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. *Structure* 1995. **3**: 1355-1366.
- Harel, M., Quinn, D.M., Nair, H.K., Silman, I. and Sussman, J.L. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of Acetylcholinesterase. Structure of a trifluoroketone-AChE complex. *J. Am. Chem. Soc.* 1996. **118**: 2340-2346.

- Haroutunian, V., Greig, N.H., Utsuki, T., Davis, K.L. and Wallace, W.C. Pharmacological modulation of Alzheimer's β -amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. *Mol. Brain. Res.* 1997. **46**: 161-168.
- Harper, J.D., Wong, S.S., Lieber, C.M. and Lansbury, P.T.Jr. Assembly of a beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. *Biochemistry.* 1999. **38**: 8972-8980.
- Harvey, A.L. The pharmacology of galanthamine and its analogues. *Pharmac. Ther.* 1995. **68**:113-128.
- Hasinoff, B.B. Kinetics of acetylthiocholine binding to electric eel Acetylcholinesterase in glycerol/water solvents of increased viscosity. Evidence for a diffusion-controlled reaction. *Biochim. Biophys. Acta.* 1982. **704**:52-58.
- Hendrickson, W.A. Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. *Science.* 1991. **254**: 51-58.
- Hock, C., Konietzko, V., Papassotiropoulos, A., Wollmer, A., Streffer, J.R., Von Rotz, R.C., Davey, G., Moritz, E. and Nitsch, R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer's disease. *Nat Med.* 2002. **8** 1270-1275.
- Hock, C., Konietzko, V., Streffer, J.R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, V., Henke, K., Moritz, E., Garcia, E., Wollmer, M.A., Umbricht, D., de Quervain, D.J.F., Hofmann, M., Maddalena, A., Papassotiropoulos, A. and Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron.* 2003. **38**: 547-554.
- Hucho, F., Järv, J. and Weise, C. Substrate-binding sites in Acetylcholinesterase. *Trends in Pharmaceutical Sciences.* 1991. **12**: 422-426.
- Jhee, S.S., Fabbri, L., Piccinno, A., Monici, P., Moran, S., Zarotsky, V., Tan, E.Y., Frackiewicz, E.J. and Shiovitz, T. First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease. *Clin. Neuropharmacol.* 2003. **26**: 164-169.
- Jones, T.A., Zhou, J.-Y., Cowan, S.W., and Kjeldgaard, M. Improved methods for building protein models in electron density maps and the

- location of errors in these models. *Acta Crystallogr. A*. 1991. **47**:110-119.
- Karlsson, E., Mbugua, P.M., Rodriguez-Ithurralde, D. Fasciculins, anticholinesterase toxins from the venom of the green mamba *Dendroaspis angusticeps*. *J. Physiol.* 1984. **79**: 232-240.
- Kawakami Y., Inoue, A., Kawai, T., Wakita, M., Sugimoto, H. and Hopfinger, A. The rationale for E2020 as a potent Acetylcholinesterase inhibitor. *Bioorg. Med. Chem.* 1996. **9**: 1429-1446.
- Knapp, R.J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J., Miller, C., Crites, G., Malatynska, E. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behaviour model. *Eur. J. Pharmacol.* 2002. **440**, 27-35.
- Koellner, G., Kryger, G., Millard, C. B., Silman, I., Sussman, J. L. and Steiner, T. Active site gorge and buried water molecules in crystal structures of Acetylcholinesterase from *Torpedo Californica*. *J. Mol. Biol.* 2000. **296**, 713-735.
- Koellner, G., Steiner, T., Millard, C. B., Silman, I. and Sussman, J. L. A neutral molecule in a cation-binding site: specific binding of a PEG-SH to Acetylcholinesterase from *Torpedo Californica*. *J. Mol. Biol.* 2002. **320**, 721-725.
- Koo, E.H. and Kopan R. Potential role of presenilin-regulated signalling pathways in sporadic neurodegeneration. *Nat. Med.* 2004. **10**: s26-s33.
- Koo, E.H., Park, L. and Selkoe, D.G. Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. *PNAS*. 1993. **90**:4748-4752.
- Kozikowski, A.P., Xia, Y., Reddy, E.R., Tuchmantel, W., Hanin, I. and Tang, X.C. Synthesis of Huperzine A and its analogues and their anticholinesterase activity. *J. Org. Chem.* 1991. **56**: 4636-4645.
- Kreimer, D.I., Dolginova, E.A., Raves, M., Sussman, J.L., Silman, I. and Weiner, L. A metastable state of *Torpedo Californica* Acetylcholinesterase generated by modification with organomercurials. *Biochemistry*. 1994. **33**: 14407-14418.

- Kronman, C., Ordentlich, A., Barak, D., Velan, B. and Schafferman, A. The “back door” hypothesis for product clearance in Acetylcholinesterase challenged by site-directed mutagenesis. *J. Biol. Chem.* 1994. **269**: 27819-27822.
- Kryger, G., Silman, I. and Sussman, J.L. Structure of Acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. *Structure.* 1999. **7**: 297-307.
- Kryger, G., Harel, M., Giles, K., Toker, L., Velan, B., Lazar, A., Kronman, C., Barak, D., Ariel, N., Shafferman, A., Silman, I. and Sussman, J.L. Structure of recombinant native E202Q mutant human Acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. *Acta Cryst.* 2000. **D56**: 1385-1394.
- Kühl, P.W. Excess-substrate inhibition in enzymology and high-dose inhibition in pharmacology: a re-interpretation. *Biochem. J.* 1994. **298**: 171-180.
- Laskowski, L.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Appl. Cryst.* 1993. **26**: 283-291.
- Layer, P.G., Weikert, T. and Alber, R. Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism. *Cell Tissue Res.* 1993. **273**: 219-226.
- Layer, P.G. and Willbold, E. Novel functions of Cholinesterases in development, physiology and disease. *Prog. Histochem. Cytochem.* 1995. **29**: 1-94.
- Lehman, D.J., Johnston, C. and Smith, A.D. Synergy between genes for Butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. *Hum. Mol. Genet.* 1997. **6**: 1933-1936.
- Lester, H.A. The response to Acetylcholine. *Scientific American* 1977. **236**: 106-118.
- Li, B., Stribley, J.A., Ticu, A., Xie, W., Schopfer, L.M., Hammond, P., Brimijoin, S., Hinrichs, S.H. and Lockridge, O. Abundant tissue Butyrylcholinesterase and its possible function in the Acetylcholinesterase knockout mouse. *J. Neurochem.* 2000. **75**: 1320-1331.

- Liston, D.R., Nielsen, J.A., Villalobos, A., Chapin, D., Jones, S.B., Hubbard, S.T., Shalaby, I.A., Ramirez, A., Nason, D. and White, W.F. Pharmacology of selective Acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. *Eur.J.Pharmacol.*2004. **486**: 9-17.
- Lustbader, J.W., Cirilli, M., Lin, C., Wie Xu, H., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Tronchese, F., Liu, S., Gunn-Moore, F., Lue, L-F., Walzer, D.G., Kuppusamy, P., Zewier, Z.L., Arancio, O., Stern, D., Yan, S.S., and Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. *Science*. 2004. **304**: 448-452.
- MacPhee-Quigley, K., Vedvick, T.S., Taylor, P. and Taylor, S.S. Profile of the disulfide bonds in Acetylcholinesterase. *J. Biol. Chem.* 1986. **261**: 13565-13570.
- Maelicke, A. and Albuquerque, E.X. New approach to drug therapy in Alzheimer's dementia. *Drug Discovery Today* 1996. **1**:53-59.
- Marchot, P., Khèlif, A., Ji, Y.-H., Mansuelle, P. and Bougis, P.E. Binding of ¹²⁵I-fasciculin to rat brain Acetylcholinesterase. The complex still binds diisopropylfluorophosphate. *J. Biol. Chem.* 1993. **268**: 12458-12467.
- Mary, A., Renko, D.Z., Guillou, C. and Thal, C. Potent Acetylcholinesterase inhibitors-design, synthesis, and structure-activity relationship of bis-interacting ligands in the galanthamine series. *Bioorg. Med. Chem.* 1998. **6**: 1835-1850.
- Massoulié, J., Pezzementi, L., Bon, S., Krejci, E. and Vallette, F.M. Molecular and cellular biology of Cholinesterases. *Prog. Neurobiol.*1993. **41**: 31-91.
- Mattson, M.P. Neurobiology: Ballads of a protein quartet. *Nature*. 2003. **422**: 385-387.
- Mazzucchelli, M., Porrello, E., Villetti, G., Pietra, C., Govoni, S. and Racchi, M. Characterization of the effect of Ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. *J. Neural. Transm.* 2003. **110**: 935-947.

- Mihailova, D. and Yamboliev, I. Pharmacokinetics of Galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. *Pharmacology* 1986. **32**: 301-306.
- Millard, C.B., Kryger, G., Ordentlich, A., Greenblatt, M., Harel, M., Raves, M.L., Segall, Y., Barak, D., Shaffermann, A., Silman, I. and Sussman, J.L. Crystal structure of aged phosphonilated Acetylcholinesterase: nerve agent reaction products at atomic level. *Biochemistry*. 1999a. **38**: 7032-7039.
- Millard, C.B., Koellner, G., Ordentlich, A., Shaffermann, A., Silman, I. and Sussman, J.L. Reaction products of Acetylcholinesterase and Vx reveal a mobile Histidine in the catalytic triade. *J.Am.Chem.Soc.* 1999b. **121**: 9883-9884.
- Mitchell, E., Khun, P. and Garman, E.F. Demystifying the Synchrotron Trip: a first time user's guide. *Structure* 1999. **7**: 111-121.
- Navaza, J. AMORE- an automated procedure for molecular replacement. *Acta Crystallogr. A* 1994. **50**, 157-163.
- Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat. Med.* 2003. **9**: 448-452.
- Otwinowski, Z., Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 1997. **276**: 307-326.
- Perola, E., Cellai, L., Lamba, D., Filocamo, L. and Brufani, M. Long chain analogs of Physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of Acetylcholinesterase. *Biochim. Biophys. Acta*. 1997. **1343**: 41-50.
- Pietra, C., Villetti, G., Bolzoni, P.T., Delcanale, M., Amari, G., Caruso, P., and Civelli, M. Cholinesterase inhibitory activity of new geneserine derivatives. In: K. Iqbal, D.F. Swaab, B. Winbald, & H.M. Wisniewski, eds. *Alzheimer disease and related disorders*. New York: John Wiley & Sons Ltd, New York. 1999.
- Pilger, C., Bartolucci, C., Lamba, D., Tropsha, A. and Fels, G. Accurate prediction of the bound conformation of galanthamine in the active site of *Torpedo Californica* Acetylcholinesterase using molecular docking. *J. Mol. Graphics Model.* 2001. **19**: 288-296, 374-378.

- Pomponi, M., Giacobini, E. and Brufani, M. Present state and future development of the therapy of Alzheimer disease. *Aging* 1990. **2**:125-153.
- Quinn, D.M. Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. *Chem. Rev.* 1987. **87**: 955-975.
- Radic, Z., Reiner, E., and Taylor, P. Role of the peripheral anionic site on Acetylcholinesterase: inhibition by substrates and coumarin derivatives. *Mol. Pharmacol.* 1991. **39**:98-104.
- Rapoport, S.I. Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease. *Proc. Natl. Acad. Sci.U.S.A.* 2000. **97**:5696-5698.
- Ravelli, R.B.G., Raves, M.L., Ren, Z., Bourgeois, D., Roth, M., Kroon, J., Silman, I. and Sussman, J.L. Static Laue diffraction studies on Acetylcholinesterase. *Acta Crystallogr.D.* 1998. **54**: 1359-1366.
- Raves, M.L., Harel, M., Ping pang, Y., Silman, I., Kozikowski, A.P. and Sussman, J.L. 3D structure of Acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. *Nat. Struct. Biol.* 1997. **4**: 57-63.
- Raves, M.L., Greenblatt, H.M., Kryger, G., Nicolas, A., Ravelli, R.B.G., Harel, M., Kroon, J., Silman, I. and Sussman, J.L. Alternative crystal forms of *Torpedo californica* Acetylcholinesterase. In: Doctor, B.P., Quinn, D.M., Rotundo, R.L. and Taylor, P. eds. *Structure and function of Cholinesterases and related proteins*. Plenum Press, New York. 1998: 372.
- Reiner, E., Aldridge, N., Simeon, V., Radic, Z. and Taylor P. Mechanism of Substrate Inhibition of Acetylcholinesterase. In: Massoulié, J., Bacou, F., Barnard, E., Chatonnet, A., Doctor, B.P. and Quinn, D.M., *Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology*. Washington, DC, American Chemical Society 1991 : 227-228.
- Riboldi-Tunncliffe, A. and Hilgenfeld, R. Cryocrystallography with oil-an old idea revived. *J. Appl. Cryst.* 1999. **32**: 1003-1005.
- Ripoll, D.R., Faerman, C.H., Axelsen, P.H., Silman, I. and Sussman, J.L. An electrostatic mechanism of substrate guidance down the aromatic

- gorge of Acetylcholinesterase. *Proc. Natl. Acad. Sci. U.S.A.* 1993. **90**:5128-5132.
- Robinson, B. and Robinson, JB. The anticholinesterase activities of the alkaloids of *Physostigma venenosum* seeds. *J. Mol. Pharmacol.* 1968. **20**: 213-217.
- Rochet, J.C., Lansbury, P.T. Jr. Amyloid fibrillogenesis: themes and variations. *Curr. Opin. Struct. Biol.* 2000. **10**: 60-68.
- Rosenberry, T. L. Catalysis by Acetylcholinesterase: evidence that the rate-limiting step for acylation with certain substrates precedes general acid-base catalysis. *Proc. Natl. Acad. Sci. U.S.A.* 1975. **72**:3834-3838.
- Rossmann, M.G. and Blow, D.M. The detection of sub-units within the crystallographic asymmetric unit. *Acta Cryst.* 1986. **15**: 24-31.
- Salih, E., Howard, S., Chishti, S.B., Cohen, S.G., Liu, W.S. and Cohen, J.B. Labelling of cysteine 231 in Acetylcholinesterase from *Torpedo nobiliana* by the active-site directed reagent, 1-bromo-2-[¹⁴C]pinacolone. *J. Biol. Chem.* 1993. **268**: 245-251.
- Santos, M.D., Alkondon M., Pereira, E.F., Aracava, Y., Eisenberg, H.M., Maelicke, A. and Albuquerque, E.X. The nicotinic allosteric potentiating ligand galanthamine facilitates synaptic transmission in the mammalian central nervous system. *Mol. Pharmacol.* 2002. **61**:1222-1234.
- Scarpini, E., Scheltens, P. and Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. *Lancet Neurology.* 2003. **2**: 539-546.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, K., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandeverd, C., Walker, S., Wogulis, M., Yednock, T., Games, D. and Seubert, P. Immunization with beta-amyloid attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature.* 1999. **400**: 173-177.
- Schorderet, M. Alzheimer's disease: fundamental and therapeutic aspects. *Experientia.* 1995. **51**: 99-105.

- Shafferman, A., Velan, B., Ordentlich, A., Kronman, C., Grosfeld, H., Leitner, M., Flashner, Y., Cohen, S., Barak, D. and Ariel, N. Substrate inhibition of Acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic centre. *EMBO J.* 1992. **11**: 3561-3568.
- Shafferman, A., Ordentlich, A., Barak, D., Kronman, C., Ber, R., Bino, T., Ariel, N., Osman, R. and Velan, B. Electrostatic attraction by surface charge does not contribute to the catalytic efficiency of Acetylcholinesterase. *EMBO J.* 1994. **13**: 3448-3455.
- Silman, I. and Futerman, A.H. Modes of attachment of Acetylcholinesterase to the surface membrane. *Eur. J. Biochem.* 1987. **170**: 11-22.
- Simon, S., Le Goff, A., Frobert, Y., Grassi, J. and Massoulié, J. The binding sites of inhibitory monoclonal antibodies on Acetylcholinesterase. Identification of a novel regulatory site at the putative "back door". *J. Biol. Chem.* 1999. **274** : 27740-27746.
- Sliz, P., Harrison, S.C. and Rosenbaum, G. How radiation damage in protein crystals depend on X-ray dose? *Structure.* 2003. **11**: 13-19.
- Specht, A., Ursby, T., Weik, M., Peng, L., Kroon, J., Bourgeois, D. and Goeldner, M. Cryophotolysis of ortho-nitrobenzyl derivatives of enzyme ligands for the potential kinetic crystallography of macromolecules. *Chembiochem.* 2001. **2**: 845-848.
- Spillantini, M.G. NGF e malattia di Alzheimer. *Le scienze.* 1999. **369**: 90-94.
- Stewart W., Kawas, C., Corrada, M. and Metter, E.J. Risk of Alzheimer's disease and duration of NSAID use. *Neurology.* 1997. **48**: 626-632.
- Sussman, J.L., Harel, M., Frolow, F., Varon, L., Toker, L., Futerman, A.H. and Silman, I. Purification and crystallization of a dimeric form of Acetylcholinesterase from *Torpedo californica* subsequent to solubilization with phosphatidylinositol-specific phospholipase C. *J.Mol.Biol.* 1988. **203**: 821-823.
- Sussman, J.L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L. and Silman, I. Atomic structure of Acetylcholinesterase from *Torpedo californica*: a prototypic acetylcholine-binding protein. *Science.* 1991. **253**: 872-879.

- Tariot, P.M., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA*. 2004. **291**: 317-324.
- Taylor, P. The Cholinesterases. *J. Biol. Chem.* 1991. **266**: 4025-4028.
- Taylor, P. and Lappi, S. Interaction of fluorescence probes with Acetylcholinesterase. The site and specificity of propidium binding. *Biochemistry*. 1975. **14**: 1989-1997.
- Trabace, L., Cassano, T., Steardo, L., Pietra, C., Villetti, G., Kendrick, K.M., and Cuomo, V. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. *J. Pharmacol. Exp. Ther.* 2000. **294**: 187-194.
- Trabace, L., Cassano, T., Cagiano, R., Tattoli, M., Pietra, C., Steardo, L., Kendrick, K.M. and Cuomo, V. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. *Brain Res.* 2001. **910**: 182-186.
- Trabace, L., Cassano, T., Loverre, A., Steardo, L. and Cuomo, V. CHF2819: pharmacological profile of a novel Acetylcholinesterase inhibitor. *CNS Drug Rev.* 2002. **8**: 53-69.
- TRIPOS Associates, Inc., 1699, South Hanley Road, Suite 303, St. Louis, MO, 63144 U.S.A.
- Verdonk, M.L., Boks, G. J., Kooijman, H., Kanters, J.A. and Kroon, J. Stereochemistry of charged nitrogen-aromatic interactions and its involvement in ligand-reception binding. *J. of Computer-Aided Mol Des.* 1993. **7**: 173-182.
- Von Sonntag, C. and Schuchmann, H.P. Suppression of hydroxyl radical reactions in biological systems: considerations based on competition kinetics. *Methods Enzymology*. 1994. **233**: 47-56.
- Wang, Y.E., Yue, D.X. and Tang, X.C. Anti-cholinesterase activity of huperzine A. *Zhongguo Yao Li Xue Bao*. Chinese. 1986. **7**: 110-113.
- Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E. and Koo, E.H. A subset of NSAIDs

- lower amyloidogenic Abeta42 independently of cyclooxygenase activity. *Nature*. 2001. **414**: 212-216.
- Weik, M., Ravelli, R.B., Kryger, G., McSweeney, S., Raves, M.L., Harel, M., Gros, P., Silman, I., Kroon, J. and Sussman, J.L. Specific chemical and structural damage to proteins produced by synchrotron radiation. *Proc. Natl.Acad.Sci. U.S.A.*2000. **97**: 623-628.
- Weinstock, M., Razin, M., Chorev, M. and Tashma, Z. Pharmacological activity of novel anticholinesterase agents of potential use in treatment of Alzheimer disease. In: Fisher, A., Hamin, I. And Lachman, P., eds. *Advances in Behavioral Biology*. New York, Plenum Press. 1986: 539-549.
- Wenfenack, T.M., Curran, G.L., Posudio, J.F. Targeting Alzheimer amyloid plaques in vivo. *Nat. Biotechnol.* 2000. **18**: 868-872.
- Windisch, M., Hutter-Paier, B., Jerkovic, L., Imbimbo, B. and Villetti, G. The protective effect of Ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. *Neurosci. Lett.* 2003. **341**: 181-184.
- Whittaker, V.P. Inhibitory mechanisms and clinical applications of anticholinesterases. *Biochem. Soc. Trans.* 1994. **22**: 729-735.
- Wong, D.M., Greenblatt, H.M., Dvir, H., Carlier, P.R., Han, Y.-F., Pang, Y.-P., Silman, I. and Sussman, J.L. Acetylcholinesterase complexed with bivalent ligands related to huperzine A: experimental evidence for species dependent protein-ligand complementarity. *J. Am. Chem. Soc.* 2003. **125**:363-373.
- Yu, G., Nishimura, M., Arawak, S., Levitan, D., Zhang, L., Tandon, A., Song, Y.Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D.S., Holmes, E., Milman, P., Liang, Y., Zhang, D.M., Xu, D.H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., Aebersold, R., Farrer, L.S., Sorbi, S., Bruni, A., Fraser, P., St George-Hyslop, P. Nicastrin modulates presenelin-mediated notch/glp-1 signal transduction and beta APP processing. *Nature*. 2000. **407**: 48-54.
- Yu, Q.S., Pei, X.F., Holloway, H.W. and Greig, N.H. Total syntheses and anticholinesterase activities of (3aS)-N(8)- norphysostigmine, (3aS)-N(8)-bisnorpheneserine, their antipodal isomers, and other N(8)-substituted analogues. *J. Med. Chem.* 1997. **40**: 2895-2901.

Yu, Q.S., Greig, N.H. and Holloway, H.W. Synthesis and anticholinesterase activities of (3aS)-N¹,N⁸-bisnorpheneserine, (3aS)- N¹,N⁸-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of Phenserine. *J. Med. Chem.* 1998. **41**: 2371-2379.

Yu, Q.S., Holloway, H.W., Utsuki, T., Brossi, A. and Grieg N.H. Synthesis of novel Phenserine-based-selective inhibitors of Butyrylcholinesterase for Alzheimer's Disease. *J. Med. Chem.* 1999. **42**: 1855-1861.

Yu, Q.S., Zhu, X., Holloway, H.W., Whittaker, N.F., Brossi, A. and Greig, N.H. Anticholinesterase activity of compounds related to geneserine tautomers.N-oxides and 1,2-oxazine. *J. Med. Chem.* 2002.**45**: 3684-3691.

www.alz.org

www.alzheimer.it

Zandi, P.P., Anthony, J.C., Hayden, K.M., Mehta, K., Mayer, L. and Breitner, J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonist: the Cache County study. *Neurology.* 2002. **59**: 880-886.